Based on 5 reviews
AI-generated from reviews on this page. Verify anything important with the company directly.
The calculator is a convenient way to estimate mortality risk from delay data. I appreciate the clear source citations. However, the interface could be more intuitive for quick comparisons. Overall, it is a useful resource for understanding the scale of the problem in prior authorization.
The project effectively bridges clinical data with administrative metrics. By applying hazard ratios to published delay figures, the team provides a quantifiable view of risk. The use of confidence intervals adds necessary statistical rigor. It is impressive how the dashboard aligns plan data with peer-reviewed mortality curves. This approach allows for a more nuanced understanding of how prior authorization affects cancer treatment outcomes. The evidence section is particularly strong, citing established medical literature. For researchers, the transparency in methodology is a significant asset.
The methodology is clear, but the specific terms for data usage in the dashboard remain unclear to me.
I have been looking for a reliable way to quantify the impact of prior authorization delays on patient outcomes, and this project seems to hit the mark. The connection between the Hanna et al. data and the insurer dashboards is well explained. It is reassuring to see confidence intervals attached to the estimates rather than just raw numbers. The methodology feels rigorous, especially since it relies on peer-reviewed sources like the BMJ study. I am curious if the calculator allows for custom delay inputs beyond standard four-week increments, or if it strictly adheres to the formula based on the published delay data. Also, does the dashboard update in real time as new plan data becomes available under the CMS rule? For someone trying to understand the broader scope of these delays, the evidence section is particularly helpful. It grounds the abstract concept of risk in actual published studies. I would like to know if there is a way to export the data for further analysis, or if it is primarily for public viewing. The distinction between correlation and causation is handled well. Still, knowing the update frequency would be useful.
Prior Authorization Accountability offers a transparent way to see how delays impact cancer treatment outcomes. The link between published delay figures and mortality risk is easy to follow. This tool helps clarify the real cost of administrative hold-ups for patients and policymakers alike.
No news yet. This is where the business shares its own updates and press.
No photos yet. Photos shared by reviewers will show up here.
Prior Authorization Accountability is a United States–based research and advocacy project that quantifies the population-level excess cancer mortality risk associated with insurance prior-authorization delays. It presents an evidence-based model built on peer-reviewed dose-response data, including a meta-analysis showing roughly a 10% higher relative risk of death for each four-week delay in starting cancer treatment. The site offers a calculator, an insurer dashboard, and three fully sourced scenarios, displaying estimates with 95% confidence intervals and full methodology. It explicitly states that it does not attribute specific deaths to individual companies, does not provide medical or legal advice, and never claims a named insurer caused a specific number of deaths.